Zimmer Total Revenue vs Net Receivables Analysis
ZBH Stock | USD 112.10 0.08 0.07% |
Zimmer Biomet financial indicator trend analysis is more than just analyzing Zimmer Biomet Holdings current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zimmer Biomet Holdings is a good investment. Please check the relationship between Zimmer Biomet Total Revenue and its Net Receivables accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Total Revenue vs Net Receivables
Total Revenue vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zimmer Biomet Holdings Total Revenue account and Net Receivables. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Zimmer Biomet's Total Revenue and Net Receivables is 0.95. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Zimmer Biomet Holdings, assuming nothing else is changed. The correlation between historical values of Zimmer Biomet's Total Revenue and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Zimmer Biomet Holdings are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Total Revenue i.e., Zimmer Biomet's Total Revenue and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.95 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Revenue
Total revenue comprises all receipts Zimmer Biomet Holdings generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Net Receivables
Most indicators from Zimmer Biomet's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zimmer Biomet Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. The Zimmer Biomet's current Tax Provision is estimated to increase to about 244.4 M, while Selling General Administrative is projected to decrease to under 2 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 4.9B | 4.9B | 5.3B | 3.6B | Total Revenue | 6.8B | 6.9B | 7.4B | 5.0B |
Zimmer Biomet fundamental ratios Correlations
Click cells to compare fundamentals
Zimmer Biomet Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zimmer Biomet fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 206.7M | 207M | 210.4M | 210.3M | 209.7M | 164.9M | |
Total Assets | 24.6B | 24.4B | 23.5B | 21.1B | 21.5B | 13.7B | |
Other Current Liab | 1.9B | 1.4B | 1.5B | 1.4B | 1.4B | 1.0B | |
Total Current Liabilities | 3.4B | 2.6B | 3.5B | 2.4B | 2.9B | 1.5B | |
Total Stockholder Equity | 12.4B | 12.2B | 12.7B | 12.0B | 12.5B | 7.4B | |
Property Plant And Equipment Net | 2.1B | 2.0B | 1.8B | 1.9B | 2.3B | 1.4B | |
Accounts Payable | 400.9M | 330M | 306.5M | 354.1M | 410.6M | 229.9M | |
Non Current Assets Total | 19.9B | 19.3B | 18.6B | 16.6B | 16.9B | 10.3B | |
Non Currrent Assets Other | 980.1M | 969.4M | 2.3B | 630.8M | 916.7M | 577.3M | |
Net Receivables | 1.4B | 1.5B | 1.3B | 1.4B | 1.4B | 975.8M | |
Liabilities And Stockholders Equity | 24.6B | 24.4B | 23.5B | 21.1B | 21.5B | 13.7B | |
Non Current Liabilities Total | 8.8B | 9.7B | 7.3B | 6.7B | 6.2B | 4.8B | |
Inventory | 2.4B | 2.5B | 2.1B | 2.1B | 2.4B | 1.4B | |
Other Current Assets | 357.1M | 741.9M | 1.1B | 522.9M | 366.1M | 401.6M | |
Other Stockholder Equity | 2.2B | 2.4B | 2.6B | 2.6B | 2.3B | 2.4B | |
Total Liab | 12.2B | 12.2B | 10.8B | 9.0B | 9.0B | 6.3B | |
Property Plant And Equipment Gross | 2.1B | 2.0B | 6.1B | 6.5B | 6.8B | 7.1B | |
Total Current Assets | 4.7B | 5.1B | 4.9B | 4.4B | 4.6B | 3.4B | |
Accumulated Other Comprehensive Income | (241.9M) | (297.8M) | (231.6M) | (179.3M) | (191M) | (181.5M) | |
Other Liab | 1.9B | 2.0B | 1.9B | 1.1B | 1.3B | 1.2B | |
Other Assets | 652.9M | 969.4M | 1.1B | 1.1B | 1.3B | 1.4B | |
Property Plant Equipment | 2.1B | 2.0B | 2.0B | 1.9B | 2.2B | 1.4B | |
Short Long Term Debt Total | 8.2B | 8.1B | 7.1B | 5.7B | 6.0B | 4.8B | |
Net Debt | 7.6B | 7.3B | 6.7B | 5.3B | 5.6B | 3.7B | |
Retained Earnings | 10.4B | 10.1B | 10.3B | 9.6B | 10.4B | 6.8B | |
Cash | 617.9M | 802.1M | 378.1M | 375.7M | 415.8M | 591.2M | |
Long Term Debt | 6.7B | 7.6B | 5.5B | 5.2B | 5.0B | 4.0B | |
Cash And Short Term Investments | 617.9M | 802.1M | 378.1M | 375.7M | 415.8M | 732.9M | |
Short Term Debt | 1.5B | 575M | 1.6B | 544.3M | 952.9M | 1.3B | |
Good Will | 9.6B | 9.3B | 8.9B | 8.6B | 8.8B | 6.0B | |
Intangible Assets | 7.3B | 7.1B | 5.5B | 5.1B | 4.9B | 4.2B | |
Treasury Stock | (6.7B) | (6.7B) | (6.7B) | (6.9B) | (6.2B) | (6.5B) | |
Net Tangible Assets | (4.5B) | (4.1B) | (2.8B) | (1.6B) | (1.5B) | (1.5B) | |
Noncontrolling Interest In Consolidated Entity | 4.7M | 5.2M | 5.7M | 6.7M | 6.0M | 5.7M | |
Retained Earnings Total Equity | 10.4B | 10.1B | 10.3B | 9.6B | 11.0B | 9.1B | |
Capital Surpluse | 8.9B | 9.1B | 9.3B | 9.5B | 10.9B | 7.5B |
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.597 | Dividend Share 0.96 | Earnings Share 5.24 | Revenue Per Share 37.006 | Quarterly Revenue Growth 0.04 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.